| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 07/22/2004 | WO2004060270A2 Compositions and methods for the diagnosis and treatment of tumor |
| 07/22/2004 | WO2004060269A2 Mda-7 and free radicals in the treatment of cancer |
| 07/22/2004 | WO2004060265A2 Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| 07/22/2004 | WO2004060264A2 Metastin derivatives and their use |
| 07/22/2004 | WO2004060262A2 Modulators of notch signalling for use in immunotherpapy |
| 07/22/2004 | WO2004060081A1 A method of improving nutrient utilisation by a mammal and a composition for use therein |
| 07/22/2004 | WO2004060041A2 Kim-1 antagonists and use to modulate immune system |
| 07/22/2004 | WO2004050844A3 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
| 07/22/2004 | WO2004050115A3 Combination treatment using exendin-4 and thiazolidinediones |
| 07/22/2004 | WO2004048558A3 Heparanase mediated cell adhesion and uses thereof |
| 07/22/2004 | WO2004046178A3 Shrew paralytic peptide for use in neuromuscular therapy |
| 07/22/2004 | WO2004044224A3 Branched polymeric prodrugs of vancomycin |
| 07/22/2004 | WO2004044223A3 Prodrugs of vancomycin with hydrolysis resistant polymer linkers |
| 07/22/2004 | WO2004044000A3 Compounds and methods for modulating functions of classical cadherins |
| 07/22/2004 | WO2004043339A3 Substituted cycloalkyl p1' hepatitis c virus inhibitors |
| 07/22/2004 | WO2004041843A3 Hop - a novel cardiac-restricted transcriptional factor potentially useful for cardiac regeneration and specification |
| 07/22/2004 | WO2004041118A3 Therapeutic compositions for drug delivery to and through covering epithelia |
| 07/22/2004 | WO2004039313A3 Preventing desensitization of receptors |
| 07/22/2004 | WO2004037235A3 Method and composition for preventing and treating solid tumors |
| 07/22/2004 | WO2004035789A9 Gene families associated with cancers |
| 07/22/2004 | WO2004035086A3 Method for treatment of demyelinating central nervous system disease using gm-csf |
| 07/22/2004 | WO2004033717A9 Autism gene |
| 07/22/2004 | WO2004031367A3 Uses of human zven proteins and polynucleotides |
| 07/22/2004 | WO2004029617A3 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 11a (pde11a) |
| 07/22/2004 | WO2004029229A3 Methods for promoting dopaminergic neuronal development by using ng4a-subfamily and wnt-ligands |
| 07/22/2004 | WO2004029081A3 Modified glp-1 peptides with increased biological potency |
| 07/22/2004 | WO2004028554A3 Skrp, astray, string, vacm associated with metabolic control |
| 07/22/2004 | WO2004027044A3 Triplex hairpin ribozyme |
| 07/22/2004 | WO2004026331A8 Peptides inhibiting specific cleaving activities of presenilins |
| 07/22/2004 | WO2004021977A3 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer |
| 07/22/2004 | WO2004019970A3 Glycopeptide antibiotic and semisynthetic derivatives thereof and their use as antiviral agents |
| 07/22/2004 | WO2004019881A9 Hypocretin administration as a treatment for obesity |
| 07/22/2004 | WO2004015058A3 Nephritis treatment by gene therapy |
| 07/22/2004 | WO2004006843A3 Combination therapies with l-fmau for the treatment of hepatitis b virus infection |
| 07/22/2004 | WO2004005529A3 GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND THERAPEUTIC USES THEREOF |
| 07/22/2004 | WO2003103743A3 Medical device for intra-lumenal delivery of pharmaceutical agents |
| 07/22/2004 | WO2003094965A3 Modulation of neural stem cells with s1p or lpa receptor agonists |
| 07/22/2004 | WO2003083046A3 Novel proteins and nucleic acids encoding same |
| 07/22/2004 | WO2003082184A3 Truncated lysostaphin molecule with enhanced staphylolytic activity |
| 07/22/2004 | WO2003077863A3 Method for overexpression of zwitterionic polysaccharides |
| 07/22/2004 | WO2003074560A3 Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto |
| 07/22/2004 | WO2003068167A3 Novel treatment for pathologies associated with oxidative damage |
| 07/22/2004 | WO2003062423A3 Method for inhibiting the expression of a target gene resulting from a chromosome aberration |
| 07/22/2004 | WO2003059949A3 A protein that mediates angiogenesis and tumour growth inhibition, its cdna, alone or in complex with an expression vector |
| 07/22/2004 | WO2003059148A3 Gene expression profiles in stomach cancer |
| 07/22/2004 | WO2003049691A3 Antisense modulation of pctaire protein kinase 1 expression |
| 07/22/2004 | WO2003044174A3 Mammary-associated serum amyloid a3 promoter sequences and uses for same |
| 07/22/2004 | WO2003022869A3 Human immunodeficiency virus envelope clycoprotein mutants and uses thereof |
| 07/22/2004 | WO2003014299A3 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 07/22/2004 | WO2003004623A3 Human secreted proteins |
| 07/22/2004 | WO2003002718A3 Identification and characterization of multiple splice variants of the mu opioid receptor gene |
| 07/22/2004 | WO2002102992A8 Novel nucleic acids, polypeptides, methods of making, and uses thereof |
| 07/22/2004 | WO2002102232A3 A novel signaling pathway for the production of inflammatory pain and neuropathy |
| 07/22/2004 | WO2002101076A3 Methods for targeted expression of therapeutic nucleic acid |
| 07/22/2004 | WO2002074239A3 Compositions and methods for the treatment and clinical remission of psoriasis |
| 07/22/2004 | US20040143861 Using satellite artificial chromosome (SATAC) as gene therapeutic tool to transform and propagate transgenic cells and treat metabolic disorders |
| 07/22/2004 | US20040143859 Novel proteins and methods for producing the proteins |
| 07/22/2004 | US20040143857 Erythropoietin analog-human serum albumin fusion |
| 07/22/2004 | US20040143104 Methods of treating diabetes and other blood sugar disorders |
| 07/22/2004 | US20040143103 Comprises nucleotide sequences coding mitogens for treating psoriasis, vision defects, tumors and arthritis |
| 07/22/2004 | US20040143100 High affinity humanized monoclonal antibodies |
| 07/22/2004 | US20040143099 for treatment or prevention of a thrombotic or coagulopathic disease, respiratory or inflammatory disease |
| 07/22/2004 | US20040143095 for treating high body temperature, appetite dysfunction, congestive heart failure, vascular disease, stress and anxiety; angiogenesis inhibitors; genetic engineering |
| 07/22/2004 | US20040143018 Thrombosis; emphysema; antihistamines; cirrhosis; antiarthritic agents; anticancer agenst |
| 07/22/2004 | US20040143016 Catalytic antioxidants and methods of use |
| 07/22/2004 | US20040143015 Mixture of antidiabetic agents and carrier; prevent, delay metabolism disorders |
| 07/22/2004 | US20040142993 Viricides |
| 07/22/2004 | US20040142989 Viricides |
| 07/22/2004 | US20040142919 Benzazepinone alpha vintegrin receptor antagonists |
| 07/22/2004 | US20040142909 Colchinol derivatives as angiogenesis inhibitors |
| 07/22/2004 | US20040142899 Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
| 07/22/2004 | US20040142898 also known as GLI-related finger protein and GLI Kruappel family member; may be associated with the regulation of a signaling pathway involved in the progression of lung cancer or the acquisition of resistance to platinum drugs |
| 07/22/2004 | US20040142896 High efficacy antisense RIalpha PKA poly-DNP oligoribonucleotides |
| 07/22/2004 | US20040142895 Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway |
| 07/22/2004 | US20040142889 fusion polypeptide, comprising a first part which is capable of binding to an antigen bearing target and a second part which is capable of binding to a cell |
| 07/22/2004 | US20040142886 use of vascular endothelial growth factor to enhance smooth muscle cell proliferation and to treat diseases associated with reduced smooth muscle cell proliferation |
| 07/22/2004 | US20040142885 host cell; gene therapy |
| 07/22/2004 | US20040142883 prolonged serum half-life to permit treatment regimens of about once every 5-7 days or longer, while retaining antibacterial properties in vivo |
| 07/22/2004 | US20040142878 N-cycloalkylglycines as HIV protease inhibitors |
| 07/22/2004 | US20040142876 peptidic phenethylamides; non-covalent inhibitors of serine protease |
| 07/22/2004 | US20040142875 "metastin" is the ligand to a G-protein-coupled orphan receptor known as OT7T175 or AXOR12; prodrug; treating cancer, hydatid mole, invasive mole, miscarriage, fetal hypoplasia, sugar dysbolism, lipid dysbolism or labor induction in a mammal |
| 07/22/2004 | US20040142874 peptides which modulate anaphylactic, endotoxic and inflammatory reactions in mammals; obtained from mammalian submandibular glands |
| 07/22/2004 | US20040142872 Polyamine modified antibodies having specific binding affinity for A beta also have increased permeability at the blood-brain barrier and can be used for passive immunization and treatment of Altzheimer's disease |
| 07/22/2004 | US20040142871 Osteoporosis treatment |
| 07/22/2004 | US20040142870 N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof |
| 07/22/2004 | US20040142869 Methods of use of recombinant vasoactive protein from salivary gland of the black fly |
| 07/22/2004 | US20040142868 administering an agent capable of activating a ciliary neurotrophic factor (CNTF) receptor |
| 07/22/2004 | US20040142867 Stabilized proteinic preparation |
| 07/22/2004 | US20040142866 Derivatives of the insulinotropic peptide exendin-4 and methods of production thereof |
| 07/22/2004 | US20040142865 methods for treating cancer patients with therapeutics that inhibit or degrade the OPN-b or OPN-c isoforms specifically, thereby leaving the innocuous OPN-a form intact and available to perform its normal functions in the cell |
| 07/22/2004 | US20040142861 at least one genetically-engineered growth factor, at least one genetically-engineered antioxidant, at least one genetically-engineered extracellular matrix component |
| 07/22/2004 | US20040142860 Central nervous system-derived immune privilege factor and uses thereof |
| 07/22/2004 | US20040142859 Method for treating neurodegenerative, psychiatric, and other disorders with deacetylase inhibitors |
| 07/22/2004 | US20040142858 Prodrugs of vancomycin with hydrolysis resistant polymer linkages |
| 07/22/2004 | US20040142857 Gemcitabine prodrugs, pharmaceutical compositions and uses thereof |
| 07/22/2004 | US20040142856 Glycoconjugation methods and proteins/peptides produced by the methods |
| 07/22/2004 | US20040142855 to facilitate allogeneic engraftment of donor cells and tissues in vivo with the resultant induction of donor-specific tolerance; can form a complex with the T cell receptor (TCR) beta chain, alone or in association with the CD3 antigen |
| 07/22/2004 | US20040142854 internalization sequence covalently linked to the modulating agent, a liposome that encapsulates the modulating agent or an antibody or ligand that binds to a cell surface receptor; alopecia |
| 07/22/2004 | US20040142853 Stimulation of hair growth by compositions containing peptide copper complexes and minoxidil |
| 07/22/2004 | US20040142852 vitamin; a metal salt that provides metal ions in vivo; and insulin or a growth hormone |